AL-Rev1

N/A

Report date: 2022/08/23 20:00:44
NME

Base Information

Drug NameAL-Rev1
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 17 inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAllosterix Pharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllosterix Pharmaceuticals LLC
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A